Solventum (FRA:KB7) Ending Cash Position: €485 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KB7 Solventum Corp FRA:KB7
28 GF Score
Price €75.60
! 8 Warning Signs
View Full Analysis

What is Solventum Ending Cash Position?

Solventum FRA:KB7 28 Ending Cash Position is €485 Mil as of Mar. 2026. GuruFocus rates FRA:KB7 with a GF Score™ of 28/100. The stock has 8 warning signs investors should review.

Solventum's Ending Cash Position for the quarter that ended in Mar. 2026 was €485 Mil.

Solventum's quarterly Ending Cash Position declined from Sep. 2025 (€1,399 Mil) to Dec. 2025 (€750 Mil) and declined from Dec. 2025 (€750 Mil) to Mar. 2026 (€485 Mil).

Solventum's annual Ending Cash Position increased from Dec. 2023 (€178 Mil) to Dec. 2024 (€728 Mil) and increased from Dec. 2024 (€728 Mil) to Dec. 2025 (€750 Mil).

Solventum Ending Cash Position Related Terms

Solventum Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Solventum's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Ending Cash Position Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 80.54 57.58 177.90 727.71 749.81

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 493.95 426.56 1,398.98 749.81 485.27
FRA:KB7
28GF Score
Solventum Corp FRA:KB7
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Solventum's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=650.748+99.064
=750

Solventum's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=760.335+-275.07
=485

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €485 Mil mean?
Solventum (FRA:KB7) has a Ending Cash Position of €485 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Solventum and its competitors.
Is Solventum's Ending Cash Position too high?
Solventum's current Ending Cash Position is €485 Mil. Overall, Solventum has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Ending Cash Position compare to COO and ALGN?
Solventum's Ending Cash Position of €485 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Solventum and its competitors. Solventum's current Ending Cash Position is €485 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current Ending Cash Position of €485 Mil. The current Ending Cash Position is €485 Mil. Solventum's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Solventum (FRA:KB7), the current Ending Cash Position is €485 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
28GF Score

Get the complete analysis for FRA:KB7

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.60
Price